ARVN
Arvinas, Inc.
$10.11
-0.79%
2026-05-08
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Key Fundamentals
Forward P/E
-2.92
EPS (TTM)
$-1.14
ROE
-16.2%
Revenue Growth (YoY)
-84.0%
Profit Margin
-30.8%
Debt/Equity
2.05
Price/Book
1.48
Beta
1.80
Market Cap
$652.4M
Avg Volume (10D)
893K
Recent Breakout Signals
No recent breakout signals detected for ARVN.
Recent Price Range (60 Days)
60D High
$14.51
60D Low
$9.73
Avg Volume
842K
Latest Close
$10.11
Get breakout alerts for ARVN
Sign up for Breakout Scanner to receive daily notifications when ARVN triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Arvinas, Inc. (ARVN) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ARVN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ARVN operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.